ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM | N213388 | ABBVIE INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AbbVie Inc. v. Teva Pharmaceuticals, Inc. et al 4 patentsANDA 217650elagolix sodium (eq. 300 mg base), estradiol (1 mg), and norethindrone acetate (0.5 mg) | D. Del. | 2023-11-07 | Terminated 2024-01-02 | — |
| D. Del. | 2023-02-03 | Terminated 2024-01-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$21.93
per ea
Lowest NADAC/Unit
$21.93
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00074101756ORIAHNN 300-1-0.5 MG/300 MG CAPS | $21.93 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.